Transcription of U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
{{id}} {{{paragraph}}}
Example: marketing
U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
Recommendations and Reports / Vol. 65 / No. 3 July 29, 2016 Medical Eligibility Criteria for Contraceptive Use, Department of Health and Human ServicesCenters for Disease Control and PreventionMorbidity and Mortality Weekly ReportRecommendations and ReportsDisclosure of RelationshipCDC, our planners, and our content experts wish to disclose they have no financial interest or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Planners have reviewed content to ensure there is no bias. This document will not include any discussion of the unlabeled use of a product or a product under investigational use, with the exception that some of the recommendations in this document might be inconsistent with package labeling. The MMWR series of publications is published by the Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), Department of Health and Human Services, Atlanta, GA citation: [Author names; first three, then et al.]
thrombosis, gestational trophoblastic disease, and migraine headaches), addition of recommendations for new medical conditions (cystic fibrosis, multiple sclerosis, use of certain psychotropic drugs, and St. John’s wort), and addition of recommendations for new contraceptive methods (ulipristal acetate for emergency contraception).
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: